Amyopathic dermatomyositis associated with immune checkpoint inhibitor therapy in lung adenocarcinoma: a case report.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) have proven efficacious in various types of cancers, including lung cancer, but they usually lead to a set of organ-specific immune-related adverse events (irAEs). In particular, checkpoint inhibitor pneumonitis (CIP) requires special attention because it is difficult to diagnose and can be potentially fatal. Accumulating real-world epidemiological data indicate that CIP is more common than previously reported. Amyopathic dermatomyositis (ADM), which shows no or minimal muscle damage, is positive for anti-melanoma differentiation-associated gene 5 (anti-MDA5) and involves unique skin findings, as well as clinical features of rapidly progressive interstitial lung disease (RP-ILD). Therefore, knowing how to differentiate between CIP and

SUBMITTER: Zhang Z 

PROVIDER: S-EPMC11912058 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature